Patients who received ipilimumab alone or in combination with nivolumab developed hypophysitis after a median of 8 weeks and therefore faster than patients who received anti-PD1 monotherapy, who developed the ir-hypophysitis after a median of 40 weeks (p < 0.001). The gene discussed is PDCD1; the disease is hypophysitis.